Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis.
Saved in:
| Title: | Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis. |
|---|---|
| Authors: | Elborn JS; Centre for Infection and Immunity, Dentistry, and Biomedical Sciences, Queens University School of Medicine, Belfast, UK., Horsley A; Centre for Respiratory Medicine and Allergy, Institute of Inflammation and Repair, University of Manchester, Manchester, UK., MacGregor G; West of Scotland CF Centre, Gartnavel General Hospital, Glasgow, UK., Bilton D; Department of Respiratory Medicine, Royal Brompton Hospital, London, UK., Grosswald R; Celtaxsys, Inc, Atlanta, Georgia, USA., Ahuja S; Celtaxsys, Inc, Atlanta, Georgia, USA., Springman EB; Celtaxsys, Inc, Atlanta, Georgia, USA. |
| Source: | Clinical and translational science [Clin Transl Sci] 2017 Jan; Vol. 10 (1), pp. 28-34. Date of Electronic Publication: 2016 Nov 02. |
| Publication Type: | Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
